logo
Plus   Neg
Share
Email

Frontier IP: Exscientia To Get Up To €240 Mln In AI-based Drug Deal With Bayer

Frontier IP Group Plc announced Friday that Artificial Intelligence- driven drug discovery company Exscientia has entered into a collaboration with Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) focused on cardiovascular disease and oncology.

Under the deal terms, Exscientia will initially work on three projects with targets agreed between both parties.

Exscientia may be eligible to receive up to 240 million euros including upfront and research payments, and for meeting near term and clinical milestones. The company may also receive sales royalties.

Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development said, "We are driving forward digital transformation in R&D as we believe that digital technologies such as AI can simplify and speed up the discovery and development of new drugs for patients. The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec.

Frontier IP currently holds a 3.25 percent stake in the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT